Meeting Banner
Abstract #4413

Neuroprotective effects of Chronic Oral Methylene Blue Treatment in Mild Traumatic Brain Injury

Lora Talley Watts 1 , Michael O'Boyle 1 , Robert Cole Boggs 1 , Shiliang Huang 1 , Justin Alexander Long 1 , Qiang Shen 1 , and Timothy Duong 1

1 Research Imaging Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States

Methylene blue (MB) has energy-enhancing and antioxidant properties. We have previously showed that a single intravenous MB dose reduces lesion volume, behavioral deficits in animal model of mild traumatic brain injury (TBI). This study evaluated the efficacy of chronic oral MB administration on mild TBI by longitudinally measuring lesion volume and functional outcome. We found that chronic oral MB treatment minimized lesion volume and functional deficits compared to vehicle-treated animals. MB has an excellent safety profile and is clinically approved for other indications. MB clinical trials on TBI can thus be readily explored.

This abstract and the presentation materials are available to members only; a login is required.

Join Here